Zentalis logo
Startup

Zentalis

See Zentalis's full profile

BOOK A DEMO
Headquarters

United States

Founded Year

2020

Total Funding

$291.9M

Employees

51 - 200

Status

Active


About Zentalis

Zentalis Pharmaceuticals Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer.

Headquarters

United States


General Information on Zentalis

Brand name Zentalis
Company name Zentalis Pharmaceuticals Inc.
Website https://zentalis.com/
Founded year 2020
Employees 51 - 200
Founding team

Kevin Bunker

Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Zentalis

Dispatch Tribunal 15.08.2022
Morgan Stanley Trims Zentalis Pharmaceuticals (NASDAQ:ZNTL) Target Price to $60.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its target price reduced by Morgan Stanley from $95.00 to $60.00 in a report published on Thursday, Stock Target Advisor reports. They currently have an overweight rating on the stock. ZNTL has been the subject of several other research reports. SVB Leerink reduced their price target on shares of Zentalis Pharmaceuticals from $67.00 to $42.00 and set an outperform rating for the company in ...

Zentalis news
American Banking News 13.08.2022
Zentalis Pharmaceuticals (NASDAQ:ZNTL) PT Lowered to $42.00

Zentalis Pharmaceuticals ( NASDAQ:ZNTL – Get Rating had its price target decreased by SVB Leerink from $67.00 to $42.00 in a research note issued to investors on Wednesday, Stock Target Advisor reports. SVB Leerink currently has an outperform rating on the stock. SVB Leerink also issued estimates for Zentalis Pharmaceuticals' Q3 2022 earnings at ($1.24) EPS, Q4 2022 earnings at ($1.28) EPS, FY2022 earnings at ($4.97) EPS, FY2023 earnings at ...

Zentalis news
American Banking News 13.08.2022
HC Wainwright Trims Zentalis Pharmaceuticals (NASDAQ:ZNTL) Target Price to $55.00

Zentalis Pharmaceuticals ( NASDAQ:ZNTL – Get Rating had its price target decreased by HC Wainwright from $120.00 to $55.00 in a report released on Wednesday, The Fly reports. HC Wainwright currently has a buy rating on the stock. Several other analysts have also commented on ZNTL. Guggenheim dropped their price objective on Zentalis Pharmaceuticals to $57.00 and set a na rating on the stock in a report on Tuesday, May 17th. Cowen started ...

Zentalis news
ETF Daily News 13.08.2022
Morgan Stanley Trims Zentalis Pharmaceuticals (NASDAQ:ZNTL) Target Price to $60.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its price objective dropped by analysts at Morgan Stanley from $95.00 to $60.00 in a research report issued on Thursday, Stock Target Advisor reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s price target points to a potential upside of 110.45% from the stock’s previous close. ZNTL has been the subject of a number of other reports. Guggenheim decreased ...

Zentalis news
Defense World 13.08.2022
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $60.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its price target cut by analysts at Morgan Stanley from $95.00 to $60.00 in a research note issued to investors on Thursday, Stock Target Advisor reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 110.45% from the stock’s current price. Several other brokerages also recently weighed in on ZNTL. Wedbush ...

Zentalis news
Watchlistnews.com 13.08.2022
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Down After Analyst Downgrade

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) gapped down before the market opened on Thursday after Morgan Stanley lowered their price target on the stock from $95.00 to $60.00. The stock had previously closed at $30.74, but opened at $29.54. Morgan Stanley currently has an overweight rating on the stock. Zentalis Pharmaceuticals shares last traded at $28.41, with a volume of 13,192 shares traded. Several other research firms have ...

Zentalis news
ETF Daily News 13.08.2022
Oppenheimer Brokers Boost Earnings Estimates for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Analysts at Oppenheimer lifted their Q3 2022 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a note issued to investors on Tuesday, August 9th. Oppenheimer analyst M. Biegler now expects that the company will earn ($1.01) per share for the quarter, up from their previous estimate of ($1.19). The consensus estimate for Zentalis Pharmaceuticals’ current full-year ...

Zentalis news
ETF Daily News 13.08.2022
SVB Leerink Analysts Boost Earnings Estimates for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Stock analysts at SVB Leerink raised their Q3 2022 EPS estimates for shares of Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 10th. SVB Leerink analyst A. Berens now expects that the company will post earnings per share of ($1.24) for the quarter, up from their previous forecast of ($1.32). SVB Leerink has a “Outperform” rating and a ...

Zentalis news
Newsdaemon.com 12.08.2022
Zentalis Pharmaceuticals Inc. (ZNTL) is destined for greater heights as its last quarter sales were 0 K

Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) kicked off on August 11, 2022, at the price of $29.54, down -8.65% from the previous trading day. During the day, the shares moved up to $30.00 and dropped to $26.85 before settling in for the closing price of $30.74. Over the past 52 weeks, ZNTL has traded in a range of $17.33-$87.19. While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay ...

Modern Readers 12.08.2022
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Fiera Capital Corp

Fiera Capital Corp boosted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 0.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 369,086 shares of the company’s stock after buying an additional 762 shares during the period. Fiera Capital Corp’s holdings in Zentalis Pharmaceuticals were worth $17,029,000 as of its most ...

Zentalis news